Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT02647437
Official study titleEffects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In AuroraSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- University of Colorado, Denver
TerminatedNCT02140788
Official study titleA Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder
This study ended early.
Location not clearly listedSchizophreniaMedication studyAges 18–60
- Countries
- Sponsor
- Duke University
CompletedNCT03189810
This study has finished and is no longer accepting participants.
In TorontoSchizophrenia, AddictionDevice studyAges 18–55
- Countries
- Canada
- Sponsor
- Centre for Addiction and Mental Health (Hospital / academic medical center)
CompletedNCT06538259
Official study titleEffects of Transcranial Direct Current Stimulation Combined With Retrieval Practice on Semantic Memory in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In LanzhouSchizophreniaDevice studyAges 19–60
- Countries
- China
- Sponsor
- Northeast Normal University
CompletedNCT06547996
Official study titleEffects of Transcranial Electrical Stimulation Combined With Retrieval Practice on Semantic Memory in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In LanzhouSchizophreniaDevice studyAges 18–60
- Countries
- China
- Sponsor
- Northeast Normal University
TerminatedNCT03838484
This study ended early.
In NashvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Vanderbilt University Medical Center
TerminatedNCT03784222
This study ended early.
Multiple locations, including BeijingSchizophreniaMedication studyAges 18–45
- Countries
- China
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
CompletedNCT00212836
What is this study about?Researchers compared asenapine and olanzapine, tracking side effects to assess safety in people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT00145496
What is this study about?Researchers compared Asenapine and Olanzapine, tracking side effects to assess safety in people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT04624243
Official study titleA Phase 2B Randomized, Double-Blind, Placebo- and Active-Controlled Trial of the Efficacy and Safety of MK-8189 in Participants Experiencing an Acute Episode of Schizophrenia
This study has finished and is no longer accepting participants.
Multiple locations, including BentonvilleSchizophreniaMedication studyAges 18–55
- Countries
- United States, Bulgaria, Croatia, + 9 others
- Sponsor
- Merck Sharp & Dohme LLC
CompletedNCT00254202
Official study titleA Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States, India
- Sponsor
- Vanda Pharmaceuticals
CompletedNCT01267188
What is this study about?This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.
This study has finished and is no longer accepting participants.
In TorontoSchizophreniaMedication studyAges 18–65
- Countries
- Canada
- Sponsor
- Neurocrine Biosciences (Biotech company)